GlobeNewswire by notified

Atico Updates Mineral Reserves and Resources for the El Roble Mine in Colombia

Share

VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) is pleased to report of an updated NI 43-101 mineral resource and reserve estimate as on March 12th 2024 for the El Roble Mine located in Colombia.

“Our infill and mine vicinity exploration drilling at El Roble mine has yielded very good results intercepting additional high-grade mineralization in proximity to current mining activity. What is particularly exciting is that we still continue to intercept further mineralization beyond the cutoff date of this report which is telling us that these areas remain open at depth and along strike,” said Fernando E. Ganoza, CEO. “Aggressive mine vicinity drilling will continue this year looking for additional massive sulphide deposits and to replace what is currently being mined.”

Resource and Reserve Estimate Highlights

  • Measured and Indicated Mineral Resources are estimated at 881 thousand tonnes averaging 3.40% Cu, and 2.98 g/t Au.
  • Proven and Probable Mineral Reserves are estimated at 828 thousand tonnes averaging 2.49% Cu, and 2.20 g/t Au.
  • A conversion rate of 88% of Measured and Indicated resources to Proven and Probable reserve categories over the current resource estimate.
  • Life of Mine extended until first quarter of 2027

El Roble Resource and Reserve Estimate

The updated mineral resource and reserve estimate for El Roble was prepared by staff and consultants of Miner SA, an Atico Mining operating subsidiary. Mr. Thomas Kelly (SME Registered Member 1696580) has reviewed the reserve estimate and Mr. Antonio Cruz (AIG Registered Member 7065) has reviewed the resource estimate and both have acted as the qualified persons as defined by Canadian National Instrument 43-101. The Mineral Reserves reported herein were estimated using the Canadian Institute of Mining, Metallurgy and Petroleum (CIM) Standards on Mineral Resources and Reserves, Definitions and Guidelines prepared by the CIM Standing Committee on Reserve Definitions and adopted by CIM Council. This reserve estimate is based on all data available through March 12, 2024.

CategoryTonnes
(000)
Cu Eq.
(%)
Cu
(%)
Au
(g/t)
Proven5283.312.471.92
Probable3003.752.542.71
Proven + Probable Reserves8283.472.492.20


CategoryTonnes
(000)
Cu Eq.
(%)
Cu
(%)
Au
(g/t)
Measured Resources5004.393.282.63
Indicated Resources3815.103.563.45
Measured + Indicated Resources8814.693.402.98


  1. Mineral Resources and Mineral Reserves are as defined by CIM definition Standards on Mineral Resources and Mineral Reserves 2014.
  2. Mineral Resources and Mineral Reserves are estimated provided above have an effective date of March 12th 2024. The Mineral Resource estimates and the Mineral Reserve estimates were prepared by the Company's Internal QPs, who have the appropriate relevant qualifications, and experience in resource mineral estimation and reserves mineral estimation.
  3. The Mineral Reserves were estimated from the M&I portions of the Mineral Resource estimates. Inferred Mineral Resources were not considered to be converted into Mineral Reserve estimates.
  4. Mineral Reserves are reported using an NSR breakeven cut-off value of 130.11 USD/t (basis 2023 cost) this value is considered for the Zeus, A, B, D, D2, Afrodita and Rosario ore bodies and using an NSR breakeven cut-off value of 74.43 USD/t is considered for the Maximus, Maximus Sur, Perseo, Goliath ore bodies.
  5. Mineral Resources are reported using an NSR cut-off grade value of US$51.05/t, this value is considered for the Maximus, Maximus Sur and Perseo deposits. And using an NSR cut-off grade of US$72.59/t for A, B, D, D2, Afrodita, Rosario and Principal ore body.
  6. Metal prices used were US$1,991.00/troy ounce Au and US$ 4.12/t Cu.
  7. Metallurgical recoveries have been considered based on historical results as of 2023. For the mine designated as low zone (Zeus, Maximus, Maximus South, Goliath and Perseus ore bodies) Cu recovery is 91.67% and Au recovery is 59.74%. For the mine designated as high zone (Principal, A, B, D, D2, Afrodita and Rosario orebodies) Cu is 93% and Au is 63%.
  8. Metal payable recovery used 92.40% for gold and 94.03% for copper (2023 commercialization basis).
  9. The average density for the ore-body was designated as follows; Goliath = 3.34t/m3, Maximus = 3.50t/m3, Maximus Sur = 3.26t/m3, Zeus = 3.53t/m3 and Perseo = 3.35t/m3. for A, B, D, D2, Afrodita, Rosario and Principal ore body the density was estimated using IDW.
  10. Mineral Resources, as reported, are undiluted.
  11. Mineral Resources are reported to 0.87% CuEq cut-off for ore-body Zeus. 0.61% CuEq cut-off for ore-bodies Goliath, Maximus, Maximus Sur and Perseo. 0.86%CuEq cut-off for ore-bodies A, B, D, D2, Afrodita, Rosario and Cuerpo Principal.
  12. CuEq for each block was calculated by multiplying one tonne of mass of each block-by-block grade for both Au and Cu by their average recovery, metal payable recovery and metal price. If the block was higher than CuEq cut-off, the block is included in the estimate (resource or reserve estimate as appropriate).
  13. CuEq is estimated considering metal price assumptions, metallurgical recovery for the corresponding mineral type/mineral process and the metal payable of the selling contract. (a) The AgEq grade formula used was: CuEq Grade = Cu Grade + Au Grade * (Au Recovery * Au Payable * Au Price) / (Cu Recovery * Cu Payable * Cu Price). (b) Metal prices considered for Mineral Reserve estimates were US$4.12/lb Cu and US$1,991/oz Au for all sites. (c) Other key assumptions and parameters include: metallurgical recoveries; metal payable terms; direct mining costs, processing costs, and G&A costs.
  14. Modifying factors for conversion of resources to reserves included consideration for planned dilution which is based on spatial and geotechnical aspects of the designed stopes and economic zones, additional dilution consideration due to unplanned events, materials handling and other operating aspects, and mining recovery factors. Mineable shapes were used as geometric constraints.
  15. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability.
  16. There is no certainty that all or any part of the Mineral Resources estimated will be converted into Mineral Reserves.
  17. There are no known political, environmental or other risks that could materially affect the development and mining of the Mineral Reserves in the El Roble mine.
  18. Figures in the table are rounded to reflect estimate precision; small differences are not regarded as material to the estimates.
  19. Reserves are estimated based on mining material that can be mined, processed and smelted.

Resource and Reserve Estimation Methodology

The Mineral Resource estimation considers channel and core samples, in addition to the underground mine mapping for the construction of three-dimensional wireframes of the lithology and mineralized bodies. Estimation of grades in the block models only considers samples located inside the mineralized bodies solid, which are applied to anomalous grade or top cut treatment and a further compositing process. The model was constructed using 2m x 2m x 2m blocks, which represents the selective mining unit (SMU). The orebodies estimation is conducted separately body by body and element by element (Cu and Au). The methods used for grade estimation are cubic inverse distance (Goliath, Maximus, Maximus Sur, Perseo, A, B, D, D2, Afrodita, Rosario and Cuerpo Principal Orebodies) and Ordinary Kriging (Zeus Orebody).

A specific density factor was assumed for each site to convert block volumes to tons for the bodies: Goliath = 3.34 t/m3, Maximus = 3.50 t/m3, Maximus Sur = 3.26 t/m3 , Zeus = 3.53 t/m3 and Perseus = 3.35 t/m3. For mineralized bodies A, B, D, D2, Afrodita and Rosario the densities were estimated with IDW. Mineral resources are reported with a limit of 0.87% CuEq cut-off for ore-body Zeus, 0.61% CuEq cut-off for ore-body Goliath, Maximus, Maximus Sur and Perseo and 0.86%CuEq cut-off for ore-body body A, B, D, D2, Afrodita, Rosario and Cuerpo Principal. For each block, the CuEq value was calculated by multiplying one ton of mass of each block grade by its average recovery, payable metal recovery, and metal price. Blocks with a CuEq grade higher than the CuEq limit were included in the resource estimate.

Proven and Probable Mineral Reserves were derived from the Measured and Indicated Resources by applying modifying factors related to mining methods, mining dilution and historical operating costs detailed as follows: mining for Zeus, A, B, D, D2, Afrodita, Rosario y Cuerpo Principal (US $61.72/t) and mining for Maximus, Maximus Sur, Goliath and Perseo (US $33.82/t) , processing (US $31.93/t), general services (US $16.79/t), on-site administration and indirect (US $10.99/t), selling and concentrate shipping (US $8.68/t). Operating costs total and comprise the lower NSR value for reserve reporting purposes. Mining dilution was estimated at variable percentages depending on the mining activity and labor.

The resource and reserve models have been validated by reconciliation against actual mined production continuously for several years with reconciliation results being acceptable for all ore bodies that have experienced a significant amount of production.

A full NI 43-101 report reviewed and approved by Mr. Thomas Kelly will be available on www.sedar.com within 45 days of this news release.

El Roble Mine

The El Roble mine is a high grade, underground copper and gold mine with nominal processing plant capacity of 1,000 tonnes per day, located in the Department of Choco in Colombia. Its commercial product is a copper-gold concentrate.

Since obtaining control of the mine on November 22, 2013, Atico has upgraded the operation from a historical nominal capacity of 400 tonnes per day to 850 tons per day by mechanizing and modernizing their mining operations and processes.

El Roble has Proven and Probable reserves of 828 thousand tonnes grading 2.49% copper and 2.20 g/t gold, at a cut-off grade of 2% copper equivalent this value is considered for the Zeus, A, B, D, D2, Afrodita and Rosario ore bodies and 1.1% is considered for the Maximus, Maximus Sur, Perseo and Goliath ore bodies as of March 12th 2024. Mineralization is open at depth and along strike and the Company plans to further test the limits of the deposit.

On the larger land package, the Company has identified a prospective stratigraphic contact between volcanic rocks and black and grey pelagic sediments and cherts that has been traced by Atico geologists for ten kilometers. This contact has been determined to be an important control on VMS mineralization on which Atico has identified numerous target areas prospective for VMS type mineralization occurrence, which is the focus of the current surface drill program at El Roble.

Qualified Persons

Mr. Thomas Kelly (SME Registered Member 1696580), advisor to the Company and a qualified person under National Instrument 43-101 standards, is responsible for ensuring that the technical information contained in this news release is an accurate summary of the original reports and data provided to or developed by Atico.

Mr. Antonio Cruz (AIG Registered Member 7065), employee of the Company and a qualified person under National Instrument 43-101 standards, is responsible for ensuring that the technical information contained in this news release is an accurate summary of the original reports and data provided to or developed by Atico.

About Atico Mining Corporation

Atico is a growth-oriented Company, focused on exploring, developing and mining copper and gold projects in Latin America. The Company generates significant cash flow through the operation of the El Roble mine and is developing its high-grade La Plata VMS project in Ecuador. The Company is also pursuing additional acquisition of advanced stage opportunities. For more information, please visitwww.aticomining.com.

ON BEHALF OF THE BOARD

Fernando E. Ganoza
CEO
Atico Mining Corporation

Trading symbols: TSX.V: ATY | OTC: ATCMF

Investor Relations
Igor Dutina
Tel: +1.604.633.9022

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the ‘‘U.S. Securities Act’’), or any state securities laws, and may not be offered or sold in the United States, or to, or for the account or benefit of, a "U.S. person" (as defined in Regulation S of the U.S. Securities Act) unless pursuant to an exemption therefrom. This press release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company in any jurisdiction.

Cautionary Note Regarding Forward Looking Statements

This announcement includes certain “forward-looking statements” within the meaning of Canadian securities legislation. All statements, other than statements of historical fact, included herein, without limitation the use of net proceeds, are forward-looking statements. Forward- looking statements involve various risks and uncertainties and are based on certain factors and assumptions. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include uncertainties relating to interpretation of drill results and the geology, continuity and grade of mineral deposits; uncertainty of estimates of capital and operating costs; the need to obtain additional financing to maintain its interest in and/or explore and develop the Company’s mineral projects; uncertainty of meeting anticipated program milestones for the Company’s mineral projects; and other risks and uncertainties disclosed under the heading “Risk Factors” in the prospectus of the Company dated March 2, 2012 filed with the Canadian securities regulatory authorities on the SEDAR website at www.sedar.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.21.5.2024 02:25:00 CEST | Press release

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® REYKJAVIK, ICELAND & PARSIPPANY, NJ— Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. “We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey, Senior Vice President, U.S. Market Access at Teva. “Biosimilars create opportunities for cost savings across the healthcare system, and SIMLANDI’s launch now offers the first citrate-free, high-concentration biosimilar to be designated interchangeable to Hu

IDEX Biometrics – Number of shares in Tranche 1 vs Tranche 2 in the private placement on 15 May 202420.5.2024 23:52:54 CEST | Press release

Reference is made to the stock exchange announcement by IDEX Biometrics ASA (the “Company”) on 15 May 2024 regarding a successful private placement of shares. By inadvertence, the announcement contained a slight error in the allocation of private placement shares between Tranche 1, as issued by the Board pursuant to an authorization to issue shares granted by the extraordinary general meeting dated 21 December 2023, and Tranche 2, to be issued subject to approval by an extraordinary general meeting to be called and scheduled for on or about 12 June 2024. The correct number of Tranche 1 shares is 27,940,213, and the correct number of Tranche 2 shares is 5,393,120, each having a par value of NOK 0.15, with a subscription price of NOK 1.65 per share in the private placement. Consequently, following the issuance of Tranche 1 shares, the Company's share capital is increased with NOK 4,191,031.95 from NOK 42,018,983.25 to NOK 46,210,015.20, and the Company will have 308,066,768 shares issued

INVNT™ ANNOUNCED AS SPONSOR AND CO-PRODUCER OF DISCOVERY STAGE AT SXSW SYDNEY® 202420.5.2024 23:00:00 CEST | Press release

Also named as an endorsed Creative Experiential Partner for the 2024 event Sydney, May 20, 2024 (GLOBE NEWSWIRE) -- INVNT™, the Experiential Disrupter Agency, has today been announced as the sponsor and co-producer of the SXSW Sydney 2024 Discovery Stage after a successful collaboration at last year’s inaugural event. For the second consecutive year, INVNT will bring its world-class expertise in production and innovative brand storytelling and “Challenge Everything” ethos to SXSW Sydney, where it will continue its legacy of hosting, curating and presenting the Discovery Stage and activating across the event’s key pillars of Tech & Innovation, Music, Games and Screen. Featured within the SXSW Sydney Tech & Innovation Expo, the 2024 Discovery Stage will play host to inspiring innovation leaders who are redefining industry norms and will be a place to explore the latest developments in technology and meet startup founders who are poised to disrupt the status quo. As last year’s Discovery

Nokia Corporation: Repurchase of own shares on 20.05.202420.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 20 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 20.05.2024 Espoo, Finland – On 20 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL370,3933.56CEUX--BATE--AQEU--TQEX--Total370,3933.56 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM20.5.2024 20:15:00 CEST | Press release

Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammationData support the potential of Dupixent as the first new treatment approach in more than a decadeand first-ever targeted therapy for COPD Paris and Tarrytown, N.Y. May 20, 2024. Late-breaking data were presented from the NOTUS phase 3 study evaluating the investigational use of Dupixent® (dupilumab) as an add-on maintenance treatment in adults with uncontrolled COPD on maximal standard-of-care inhaled therapy (nearly all on triple therapy) and evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL). The NOTUS study confirmed the positive results demonstrated in the landmark phase 3 BOREAS s

HiddenA line styled icon from Orion Icon Library.Eye